About Sinfonia Biotherapeutics
Sinfonia Biotherapeutics is a clinical stage company motivated by the need to transform the treatments of patients suffering from pain and devastating neurological diseases.
Building on an innovative tradition in science with deep roots in the Karolinska institute, we develop next generation biotherapeutics.
We have footprints in both Sweden and US to facilitate our global presence, research collaborations, and partnering to deliver value for patients and investors
Our Leadership Team
Lars Wahlberg, MD, PhD
CEO/CMO
Neurosurgeon, translational scientist, and entrepreneur
>20 years of biotechnology R&D experience in developing biologics-based therapies for neurological disorders
Johan Lundkvist, As. Prof
COO
Neurobiologist and cellbiologist by training
Associate Professor at Karolinska Institute in 2005
>17 years industrial leadership experience from small biotech start-ups and large pharma within neurological disorders
An van Es-Johansson, MD
Head Clinical Development
Physician , entrepreneur with extensive Board experience
> 30 years international experience in big pharma and biotech companies with focus on Clinical Development, Regulatory and Pharmacovigilance
Bob Blomquist
Corporate Development
Business leader with operational experience in Fortune 500 and new venture startups
>35 years of healthcare industry experience, including biopharmaceuticals, diagnostics and medical devices
Advisor to private equity and biopharma
Anthony Rossomando, MD, PhD
CDO
Olof Larsson, PhD,
CSO
Pharmacologist with core expertise in pain
Kristofer Svensson, B.Sc
CFO
B.Sc in Business Administration and Economics
Held several executive finance positions in the medtech field Since 2017.
Thomas Pollare, MD, PhD
Chairman
Experienced advisor and investor, including partner and member of 3i Global Healthcare team
> 25 years health care industry experience with several executive positions in major pharma companies and smaller biotechs
Experience from over 30 board positions